Browsing Tag
United States
1080 posts
Can North America build a mine-to-battery lithium chain without relying on China?
North America has lithium ambition, but China still dominates processing. The real test is turning mines into battery-grade supply.
US gasoline prices surge 28% since Iran war began as Hormuz closure persists
US gasoline at $4.17 marks a four-year high. The harder question is whether the Iran war stalemate forces Washington or Tehran to blink first.
What Meta Critical Minerals Inc.’s Arcadia Project deal means for U.S. defense and nuclear mineral security
Find out how Meta Critical Minerals Inc.’s Arcadia Project could reshape U.S. defense and nuclear mineral supply chains and what it means for investors today.
Can Europe’s Critical Raw Materials Act turn lithium projects into bankable infrastructure?
Europe wants lithium sovereignty, but projects still need bankable economics. The Critical Raw Materials Act now faces its financing test.
Why Goldman Sachs still sees $160bn in IPO proceeds despite fewer expected listings
Fewer IPOs, same $160bn target. Goldman Sachs’ reset shows why 2026 listings may depend on mega-deals. Read the full analysis.
Islamic State claims Adamawa Guyaku attack: 29 dead as Governor Ahmadu Umaru Fintiri visits affected rural communities
ISIS claimed Adamawa's Guyaku attack via Telegram. The harder question: why prior security alerts did not stop 29 deaths at a rural football match.
PCI Pharma Services bets over $1bn on US sterile fill-finish capacity as drug supply chains localize
Drugmakers want US capacity, but sterile fill-finish remains scarce. PCI Pharma Services is betting over $1B that resilience now wins contracts.
Verizon Communications (VZ) stock gains as Q1 2026 earnings reset turnaround debate
Verizon finally has subscriber momentum. Frontier debt, fiber growth, and cash flow now decide whether the VZ turnaround can hold.
Sun Pharmaceutical (NSE: SUNPHARMA) bets $11.75bn on Organon (NYSE: OGN) to become a top global pharma player
Sun Pharma is borrowing scale to escape the generics trap. Organon could reshape its global pharma identity if execution holds.
Paradigm Biopharmaceuticals (ASX: PAR) raises A$14m as Phase 3 osteoarthritis trial enters decisive window
Paradigm Biopharmaceuticals has more cash, but Zilosul still needs Phase 3 proof. ASX:PAR now turns from funding risk to data risk.